Galmed Pharmaceuticals Ltd. Operating Income Loss

Quick Answer

Galmed Pharmaceuticals Ltd. reported Operating Income Loss of -$30.21 million for the year ending 2020.

  • Galmed Pharmaceuticals Ltd. showed a decrease of -35.0% in Operating Income Loss from 2019 to 2020.
  • This data is from Galmed Pharmaceuticals Ltd.'s annual report (Form 10-K), filed with the SEC on March 18, 2021.
  • XBRL data for this metric is available from 2017 to 2020 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2017 to 2020), Galmed Pharmaceuticals Ltd.'s Operating Income Loss has declined by 144.3%.
  • Historical annual values: Fiscal year 2020: -$30.21 million | Fiscal year 2019: -$22.38 million | Fiscal year 2018: -$10.72 million | Fiscal year 2017: -$12.36 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: